India Ceftriaxone Market to grow at a steady rate During the Forecast Period

Growing prevalence of bacterial infections is expected to drive the growth of India ceftriaxone market during the forecast period.

According to TechSci Research report, “India Ceftriaxone Market By Dose (100 mg, 200 mg, 250 mg, 500 mg and Others), By Source (In-house v/s Contract Manufacturing Organizations), By Form (Intramuscular Injection, Intravenous Injection, Infusion, Others), By Distribution Channel (Online v/s Offline), By Application (Endocarditis, Meningitis, Pneumonia, Bone and Joint Infections, Intra-Abdominal Infections, Skin Infections, Urinary Tract Infections, Gonorrhoea, Others), By End User (Adult v/s Paediatric), By Company, By Region, Forecast & Opportunities, FY2026”, the India Ceftriaxone market is expected to grow at a steady rate during the forecast period. The medication is very effective in treating lower respiratory tract infections which is projected to boost the market share. Moreover, in combination with doxycycline or azithromycin, ceftriaxone is recommended for the treatment of gonorrhea which is further expected to fuel the market growth through FY2026. Furthermore, ongoing technological innovation and advancement in order to enhance the performance of the product by major market players is projected to bode well for the market growth in the next 5 years. However, side-effects associated with drug consumption such as pain at the site of injection and allergic reactions can restrict the market growth over the next few years. Moreover, in some severe cases, C. difficile associated diarrhea, seizures, gall bladder disease, and hemolytic anemia can occur. This can further reduce the usage and application of the drug thereby hindering the market growth during the forecast period.

Browse XX market data Tables and XX Figures spread through XXX Pages and an in-depth TOC on “ India Ceftriaxone Market”

https://www.techsciresearch.com/report/india-ceftriaxone-market/5158.html

The India ceftriaxone market is segmented based on dose, source, form, distribution channel, application, end user, company, and region. Based on application, the market can be fragmented into endocarditis, meningitis, pneumonia, bone and joint infections, intra-abdominal infections, skin infections, urinary tract infections, gonorrhea, others. The gonorrhea segment dominated the market until 2017 and is further forecasted to maintain its dominance during the forecast period as well. This dominance can be accredited to rising cases of gonorrhea in the country as there are more than 10 million cases per year. Based on source, the market can be categorized into in-house v/s contract manufacturing organizations. Contract manufacturing organizations segment is expected to witness significant growth in the market in the next 5 years as it saves cost and maximize profits.

Radicura Pharmaceuticals Pvt. Ltd, Wockhardt Limited (Taurus), Nectar Lifesciences Ltd., Qilu Pharmaceutical India Pvt. Ltd., Mankind Pharma Ltd., Fresenius Kabi India Pvt. Ltd., Virchow Healthcare Private Limited, Orchid Pharma Ltd., Ikon Remedies Pvt. Ltd., IPCA Laboratories Ltd. and others are some of the leading players operating in India ceftriaxone market. Companies operating in the market are using Go to Market strategies such as product launches, mergers and acquisitions, customer focus approach and research collaborations to boost their share and increase their geographic reach.

Download Free Sample Report@
https://www.techsciresearch.com/sample-report.aspx?cid=5158

Customers can also request for 10% free customization on this report.

“India ceftriaxone market is expected to witness growth during the forecast period as it is used to treat organisms that are likely to show resistance to many other antibiotics. In addition to this, Ceftriaxone medications also used before surgery and following a bite wound in order to prevent infection. This is further expected to create lucrative opportunities for the market growth of India Ceftriaxone market over the next five years.” said Mr. Karan Chechi, Research Director with TechSci Research, a research based India management consulting firm.

“India Ceftriaxone Market By Dose (100 mg, 200 mg, 250 mg, 500 mg and Others), By Source (In-house v/s Contract Manufacturing Organizations), By Form (Intramuscular Injection, Intravenous Injection, Infusion, Others), By Distribution Channel (Online v/s Offline), By Application (Endocarditis, Meningitis, Pneumonia, Bone and Joint Infections, Intra-Abdominal Infections, Skin Infections, Urinary Tract Infections, Gonorrhoea, Others), By End User (Adult v/s Paediatric), By Company, By Region, Forecast & Opportunities, FY2026”, has evaluated the future growth potential of India ceftriaxone market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in India ceftriaxone market.

Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: sales@techsciresearch.com